PCT WORLD INTELLECTUAL PROPERTY ORGANIZATION
International Bureau

INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(51) International Patent Classification 7 : A61K 41/00, 49/00

A1

(11) International Publication Number: WO 00/01414

(43) International Publication Date: 13 January 2000 (13.01.00)

(21) International Application Number: PCT/US99/15199

(22) International Filing Date: 6 July 1999 (06.07.99)

(30) Priority Data:
09/110,509 6 July 1998 (06.07.98) US

(71) Applicant *(for all designated States except US)*: PHARMACYCLICS, INC. [US/US]; 995 E. Arques Avenue, Sunnyvale, CA 94086–4521 (US).

(72) Inventors; and
(75) Inventors/Applicants *(for US only)*: WOODBURN, Kathryn, W. [AU/US]; 330 N. Mathilda Avenue #114, Sunnyvale, CA 94086 (US). YOUNG, Stuart, W. [US/US]; 45 Las Piedras, Portola Valley, CA 94028 (US).

(74) Agent: NORBERG, Gloria, L.; Akin, Gump, Strauss, Hauer & Feld, LLP, Suite 1900, 816 Congress Avenue, Austin, TX 78701 (US).

(81) Designated States: AE, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CU, CZ, DE, DK, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, UA, UG, US, UZ, VN, YU, ZA, ZW, ARIPO patent (GH, GM, KE, LS, MW, SD, SL, SZ, UG, ZW), Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European patent (AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG).

Published
With international search report.
Before the expiration of the time limit for amending the claims and to be republished in the event of the receipt of amendments.

(54) Title: USE OF TEXAPHYRINS IN MACROPHAGE–MEDIATED DISEASE

(57) Abstract

The present invention provides methods for treating disease of a subject in need thereof by sensitizing the effects of a co–therapeutic agent in macrophages. The method comprises administering a texaphyrin and a co–therapeutic agent to the subject. Texaphyrins are provided for enhancing the cytotoxicity of therapeutic agents in macrophage–mediated disease since texaphyrins have been shown to accumulate in macrophage.